Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma Research Letter

  

Authors:	Stuver, R.; Noy, A.; Vardhana, S. A.; Zelenetz, A. D.; Moskowitz, A. J.
Title:	Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
Keywords:	adult; cancer chemotherapy; clinical article; controlled study; treatment response; aged; survival analysis; overall survival; drug approval; gemcitabine; follow up; antineoplastic agent; letter; progression free survival; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; cohort analysis; retrospective study; cancer therapy; hodgkin disease; age; monoclonal antibody; patient care; lymphoma, non-hodgkin; tumor recurrence; drug cytotoxicity; disease exacerbation; non-hodgkin lymphoma; antibodies, monoclonal, humanized; humans; human; male; female; pembrolizumab
Journal Title:	British Journal of Haematology
Volume:	204
Issue:	2
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2024-02-01
Start Page:	e17
End Page:	e20
Language:	English
DOI:	10.1111/bjh.19178
PUBMED:	37905372
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175492094&doi=10.1111%2fbjh.19178&partnerID=40&md5=9caeb337acf28e2faac1f65a487d4c96
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK authors: Robert Stuver -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/213988